Type 1 Diabetes Research - OmniBio CEO Dr. James Crapo
Description: OmniBio CEO Dr. James Crapo talks about the important research taking place with Alpha-1 Antitrypsin (AAT). This safe and powerful molecule is being used in trials for type 1 diabetes and Graph vs. Host disease (GVH). OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: http://OmniBioPharma.com Facebook: http://goo.gl/ue8ou LinkedIn: http://goo.gl/te3ly Visit http://OmniBioPharma.com/investor-relations for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: http://WestMountainAM.com/FB Twitter: http://WestMountainAM.com/TW LinkedIn: http://WestMountainAM.com/LI Blog: http://WestMountainAM.com/blog
Related tags: graft host disease bone marrow transplant clinical trials alpha type 1 mellitus research cure alpha-1 antitrypsin aat jdrf juvenile children's diabetes foundation pharmaceutical industry stock investment opportunity angel investor equity development public company business finance funding portfolio venture capital startup small cap market financing healthcare health care medical WestMountain West Mountain Asset Management Omni Bio James Crapo Charles Dinarello University of Colorado
Embed: